These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

450 related items for PubMed ID: 19084082

  • 1. Reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering: a role for fenofibrate. Introduction.
    Sacks FM.
    Am J Cardiol; 2008 Dec 22; 102(12A):1L-3L. PubMed ID: 19084082
    [No Abstract] [Full Text] [Related]

  • 2. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    Jones PH.
    Am J Cardiol; 2008 Dec 22; 102(12A):41L-47L. PubMed ID: 19084089
    [Abstract] [Full Text] [Related]

  • 3. Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus.
    Steiner G.
    Am J Cardiol; 2008 Dec 22; 102(12A):28L-33L. PubMed ID: 19084087
    [Abstract] [Full Text] [Related]

  • 4. Solvay addresses unmet needs in the management of hypertensive patients with cardiometabolic and lipid disorders.
    Cardiovasc J Afr; 2009 Dec 22; 20(1):73-4. PubMed ID: 19287821
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate.
    Sacks FM.
    Am J Cardiol; 2008 Dec 22; 102(12A):34L-40L. PubMed ID: 19084088
    [Abstract] [Full Text] [Related]

  • 9. [Lipid-lowering cardiovascular prevention in type 2-diabetes. Statins are effective according to the FIELD study].
    Båvenholm P, Attvall S, Nilsson PM.
    Lakartidningen; 2008 Dec 22; 103(35):2462-6. PubMed ID: 17002161
    [No Abstract] [Full Text] [Related]

  • 10. Combination therapy in the management of mixed dyslipidaemia.
    Cannon CP.
    J Intern Med; 2008 Apr 22; 263(4):353-65. PubMed ID: 18324928
    [Abstract] [Full Text] [Related]

  • 11. Fenofibrate and cardiovascular risk: a synopsis and commentary on (FIELD).
    Bailey CJ.
    Diabet Med; 2006 Feb 22; 23(2):109-12. PubMed ID: 16433706
    [No Abstract] [Full Text] [Related]

  • 12. The current unmet need in type 2 diabetes mellitus: addressing glycemia and cardiovascular disease.
    Levy P.
    Postgrad Med; 2009 May 22; 121(3 Suppl 1):7-12. PubMed ID: 19494472
    [Abstract] [Full Text] [Related]

  • 13. Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD.
    Vergès B.
    Curr Opin Lipidol; 2006 Dec 22; 17(6):653-8. PubMed ID: 17095910
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Combination statin-fibrate therapy: safety aspects.
    Franssen R, Vergeer M, Stroes ES, Kastelein JJ.
    Diabetes Obes Metab; 2009 Feb 22; 11(2):89-94. PubMed ID: 18518891
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications.
    Cannon CP.
    Am J Cardiol; 2008 Dec 22; 102(12A):5L-9L. PubMed ID: 19084083
    [Abstract] [Full Text] [Related]

  • 19. Prevalence and treatment of metabolic syndrome in adolescents with type 2 diabetes.
    Sanders BH, Lubsch LM, West DS.
    Ann Pharmacother; 2006 Sep 22; 40(9):1517-21. PubMed ID: 16896016
    [Abstract] [Full Text] [Related]

  • 20. ACCORD and Risk-Factor Control in Type 2 Diabetes.
    Nilsson PM.
    N Engl J Med; 2010 Apr 29; 362(17):1628-30. PubMed ID: 20228405
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.